Mission Statement, Vision, & Core Values (2025) of Terumo Corporation.

An Overview of Terumo Corporation

An Overview of Terumo Corporation

Founded in 1921, Terumo Corporation has established itself as a prominent player in the global medical technology sector. The company is headquartered in Tokyo, Japan, and operates over 20 manufacturing facilities across the world. Terumo specializes in a wide range of products, including vascular intervention, blood management, cardiac and vascular surgery, and diabetes care. As of 2024, Terumo's sales reached approximately ¥1.03 trillion (roughly $7.1 billion), highlighting its strong market presence and extensive distribution capabilities.

Terumo's product lines include intravenous catheters, blood bags, and infusion systems. The company has been particularly successful in its blood management segment, which has seen significant demand due to increasing healthcare needs globally. The focus on innovation has allowed Terumo to introduce advanced products such as the Glove Bag and the TEYDEK® blood management system, further solidifying its reputation in the industry.

Company's Financial Performance in Latest Financial Reports

In the latest financial report for the fiscal year ending March 2024, Terumo Corporation reported a record-breaking revenue of ¥1.03 trillion, a remarkable increase of 12% compared to the previous year. This growth was primarily driven by strong sales in vascular intervention products, which contributed approximately ¥400 billion (around $2.8 billion) to total revenue.

Operating income for the period was reported at ¥150 billion (about $1.04 billion), resulting in an operating margin of 14.6%. The company's net income stood at ¥100 billion (approximately $700 million), reflecting a net profit margin of 9.7%.

Geographically, Terumo saw significant growth in the Asia-Pacific region, totaling over ¥500 billion in sales, an increase of 15% year-over-year. The North American market also performed strongly, contributing ¥300 billion (around $2.1 billion), driven by increased demand for blood management products.

Leading Company in the Industry

Terumo Corporation's commitment to innovation and quality has positioned it as a leader in the medical technology industry. The company's consistent investment in research and development, totaling ¥50 billion in FY 2024, underscores its strategy to enhance product offerings and address evolving healthcare challenges.

With its advanced product portfolio and strong global presence, Terumo continues to expand its market share across key segments. This growth trajectory places Terumo among the top companies within the healthcare sector, recognized for delivering quality products and services that meet the needs of medical professionals and patients alike. For further insights into Terumo's ongoing success and strategic initiatives, more detailed information can be explored below.

Mission Statement of Terumo Corporation

Mission Statement of Terumo Corporation

Terumo Corporation’s mission statement focuses on contributing to society through healthcare innovations, emphasizing the importance of quality and reliability in its products and services. This mission is vital for guiding Terumo's long-term goals, reinforcing its commitment to patient safety and enhancing the quality of life worldwide.

Core Component 1: Commitment to Quality

Terumo’s first core component underscores its dedication to delivering high-quality medical devices and services. The company believes that quality is paramount in healthcare, directly impacting patient outcomes. Terumo achieved a 92% rating in customer satisfaction surveys in 2023, showcasing its focus on maintaining standards high enough to meet diverse healthcare needs.

The investment in quality assurance protocols is evident in Terumo's sustained market position, enabling the company to maintain a strong foothold in the global medical device market, which was valued at approximately $432 billion in 2020 and is projected to grow at a CAGR of 5.4% from 2021 to 2028.

Core Component 2: Innovation in Healthcare

The second core aspect of Terumo’s mission statement emphasizes innovation. The company continually invests in research and development (R&D) to create advanced medical technologies. In 2023, Terumo allocated approximately 8.5% of its revenue to R&D, totaling around 76 billion JPY.

• Development of new blood transfusion systems.
• Advancements in minimally invasive surgery products.
• Innovative drug delivery systems for easier patient access.

With over 1,000 patents granted worldwide, Terumo’s commitment to innovation supports its mission to provide cutting-edge solutions that meet the evolving needs of healthcare professionals and patients.

Core Component 3: Global Community Support

Terumo Corporation aims to enhance the community's health and well-being through its operations. This includes collaboration with local healthcare systems and stakeholders to improve access to medical care. In 2022, Terumo contributed more than 3 billion JPY to various global health initiatives, such as vaccination programs and disaster relief efforts.

In addition, Terumo has a presence in over 160 countries, ensuring that its products and innovations reach diverse populations. The company’s community outreach programs have benefited approximately 2 million people worldwide.

Through these core components of its mission statement, Terumo Corporation strives to create a positive impact in the healthcare sector, aligning its corporate goals with societal needs.

Vision Statement of Terumo Corporation

Vision for Global Healthcare Advancement

Terumo Corporation aims to contribute to advancing global healthcare by innovating and providing high-quality medical products. The company focuses on improving patient outcomes while ensuring safety and efficiency in medical procedures. The vision in 2024 emphasizes a commitment to sustainable healthcare practices and enhancing the quality of life for patients worldwide.

Commitment to Innovation

Innovation is a core component of Terumo's vision. The company invests heavily in research and development (R&D), allocating approximately 8.5% of its annual revenue to this area. In the fiscal year 2022, Terumo reported R&D expenses of about ¥35 billion (approximately $300 million), underscoring its commitment to advancing medical technologies and solutions.

Focus on Patient-Centric Solutions

Terumo’s vision emphasizes a patient-centric approach, which is reflected in its product offerings. The company has launched over 200 new products in the last three years, catering to various medical needs like cardiovascular, diabetes care, and blood management. Their strategy focuses on understanding patient needs through extensive feedback and collaboration with healthcare professionals.

Global Expansion Strategy

The vision also includes expanding Terumo's global presence. In fiscal year 2023, the company reported a revenue increase of 10% year-over-year, reaching approximately ¥700 billion (around $5.9 billion). This growth is primarily attributed to successful market entries in regions such as Southeast Asia and Latin America, enhancing their ability to deliver quality healthcare solutions globally.

Commitment to Sustainability

Sustainability is a fundamental pillar of Terumo’s 2024 vision. The company has committed to reducing its carbon footprint by 30% by 2030. Terumo has undertaken initiatives such as implementing eco-friendly manufacturing processes and sustainability assessments in supply chain operations. In 2023, they reported a reduction in greenhouse gas emissions by 15% from the previous year.

Core Values of Terumo Corporation

Integrity

Integrity is a core value that Terumo Corporation emphasizes in its operations. The company believes that ethical behavior and transparent communication are essential for building trust with stakeholders.

In 2023, Terumo Corporation reported a net income of ¥45.8 billion (approximately $413 million), reflecting the company’s commitment to maintain ethical financial practices. The company has implemented a robust compliance program, ensuring adherence to laws and regulations across all markets.

• Terumo established an Ethics Committee to oversee compliance and ethical practices.
• In 2022, Terumo provided 15,000 hours of training on compliance and ethics to its employees globally.

Innovation

Innovation drives Terumo's growth and helps to provide cutting-edge healthcare solutions. The company invests heavily in research and development to ensure that it remains at the forefront of the medical technology sector.

For the fiscal year ending March 2023, Terumo allocated approximately 8.5% of its revenue to R&D, amounting to about ¥33 billion (around $297 million). The company launched several new products to enhance patient care, including advanced catheter systems and smart infusion devices.

• Terumo’s Precision Medicine initiative, which integrates data analytics for personalized treatment solutions, was a major focus in 2023.
• The company filed 120 new patents in the past year, underscoring its commitment to innovative medical technologies.

Respect

Respect is integral to Terumo’s corporate culture. The company places high importance on respect among employees, customers, and communities. This principle fosters teamwork and collaboration.

Terumo Corporation has implemented several initiatives to promote diversity and inclusion. As of 2023, women represented 40% of its management positions globally, highlighting the company’s commitment to a diverse workforce.

• The company has established the Terumo Diversity & Inclusion Program, which seeks to provide equal opportunities and empower underrepresented groups.
• In the past year, Terumo supported over 200 community health programs worldwide, reflecting its respect for the communities it serves.

Excellence

Excellence is a fundamental core value that drives Terumo to achieve high standards in its products and services. The company’s commitment to quality is evident in its rigorous testing and quality assurance processes.

In 2023, Terumo maintained a 99.5% product performance rate across its product lines, demonstrating its dedication to excellence in manufacturing and service delivery.

• Terumo implemented a continuous improvement program known as Kaizen, which has improved operational efficiency by 15% over the last two years.
• The company achieved ISO 13485 certification for all its manufacturing facilities, ensuring adherence to high-quality standards in the medical device industry.

Teamwork

Teamwork at Terumo Corporation fosters collaboration and enhances problem-solving in pursuit of the company’s mission. This value is reflected in how teams come together for common goals.

Through its Global Collaboration Framework, Terumo has enhanced its project delivery efficiency by 20% in 2023, bringing together multidisciplinary teams from different regions.

• Terumo hosts biannual team-building workshops that involve over 5,000 employees globally to strengthen teamwork and cohesion.
• The company’s cross-functional teams successfully launched a new product line that generated ¥10 billion (approximately $90 million) in revenue within its first year.